. Author manuscript; available in PMC: 2012 Sep 1.

Published in final edited form as: J Natl Compr Canc Netw. 2011 Sep 1;9(9):1060–1071. doi: 10.6004/jnccn.2011.0087

Table 2.

Selected Trials of Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Study	No. Patients	Regimen	EFS/DFS/FFS (%)	OS (%)
Sirohi et al.⁹	195	MBE/ME	5-y: 44; 10-y: 37	5-y: 55; 10-y: 49
			PR: 44; NR: 14	PR: 59; NR: 17
Stiff et al.⁴³	81	E, Cy, TBI	5-y: 41	5-y: 54
Sureda et al.⁸	357	Various	5-y: 49	5-y: 57
Tarella et al.⁴⁴	102	Mitx/Must	5-y: 53; CR: 78	5-y: 64; CR: 88
			PR: 41; NR: 7	PR: 58; NR: 13
Wadehra et al.⁴⁵	127	BuCyE	5-y: 48	5-y: 51
Czyz et al.⁴⁶	341	Various	5-y: 45; CS: 62	5-y: 64; CS: 79
			Res: 46	CR: 77; PR: 71;
				< PR: 33
Engelhardt et al.⁴⁷	115	Various	5-y: 46	5-y: 58
Lavoie et al.⁴⁸	100	Various		15-y: 54
				First relapse: 67
				Primref: 39
				Adv: 29

Abbreviations: Adv, advanced disease; B, carmustine; Bu, busulfan; CR, complete remission; CS, chemosensitive; Cy, cyclophosphamide; DFS, disease-free survival; E, etoposide; EFS, event-free survival; FFS, failure-free survival; M, melphalan; Mitx, mitoxantrone; Must, mustard; NR, no response; OS, overall survival; PR, partial remission; Primref, primary refractory; Res, resistant disease; TBI, total body irradiation.